Matrix metalloproteinase 2 expression and disease-free survival of patients with osteosarcoma: a meta-analysis.

Expresión de la metaloproteinasa de matriz 2 y supervivencia libre de enfermedad de pacientes con osteosarcoma: un metanálisis

• Tianshu Gao Nanjing Medical University, Wuxi, Jiangsu Province, China. https://orcid.org/0000-0002-5524-0234
• Zhenting Wang Nanjing Medical University, Wuxi, Jiangsu Province, China. https://orcid.org/0000-0001-7329-1505
• Yi Liu Nanjing Medical University, Wuxi, Jiangsu Province, China. https://orcid.org/0000-0003-0350-9008

DOI: https://doi.org/10.54817/IC.v64n2a10

Keywords: meta-analysis, MMP-2, osteosarcoma, prognosis

Abstract

Numerous studies indicate the influence of matrix metalloproteinase-2 (MMP-2) overexpression in osteosarcoma (OS) outcomes. A previous study has systematically analyzed the correlation between MMP-2 expression and the prognosis of  OS. However, the results of subsequent studies remain inconsistent. Therefore, a meta-analysis in terms of the prognostic value of MMP-2 expression in OS was conducted. We employed the Newcastle-Ottawa scale (NOS) to evaluate the quality of the studies. Five studies involving 284 patients were included. The relative risk (RR) with a corresponding 95% confidence interval (95%CI) was calculated to appraise the predictive value of MMP-2 positive expression for OS recurrence and metastasis, and lower disease-free survival. It was indicated by the results that MMP-2 positive individuals with OS had higher recurrence and metastasis rates than negative individuals (RR=1.85, 95%CI:1.16-2.93, p<0.01). Sensitivity analysis showed that the combined RR was stable. There was no significant change, independently of whichever article was excluded.

References

Biazzo A, De Paolis M. Multidisciplinary approach to osteosarcoma. Acta Orthop Belg 2016;82(4):690-698. PMID: 29182106.

Corre I, Verrecchia F, Crenn V, Redini F, Trichet V. The osteosarcoma microenvironment: a complex but targetable ecosystem. Cells 2020;9(4):976. doi: 10.3390/ cells9040976.

Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 2015;33(27):3029-3035. doi: 10.1200/JCO.2014.59.4895.

Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012;2012:704872. doi: 10.1155/2012/704872.

Jafari F, Javdansirat S, Sanaie S, Naseri A, Shamekh A, Rostamzadeh D, Dolati S. Osteosarcoma: A comprehensive review of management and treatment strategies. Ann Diagn Pathol 2020;49:151654. doi: 10.1016/j.anndiagpath.2020.151654.

Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci 2017;147:1-73. doi: 10.1016/bs.pmbts.2017.02.005.

Deng W, Peng W, Wang T, Chen J, Zhu S. Overexpression of MMPs functions as a prognostic biomarker for oral cancer patients: a systematic feview and meta-analysis. Oral Health Prev Dent 2019;17(6):505-514. doi: 10.3290/j.ohpd.a43636.

Liu C, Li Y, Hu S, Chen Y, Gao L, Liu D, Guo H, Yang Y. Clinical significance of matrix metalloproteinase-2 in endometrial cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97(29):e10994. doi: 10.1097/MD.0000000000010994.

Scheau C, Badarau IA, Costache R, Caruntu C, Mihai GL, Didilescu AC, Constantin C, Neagu M. The role of matrix metallo-proteinases in the epithelial-mesenchymal transition of hepatocellular carcinoma. Anal Cell Pathol (Amst) 2019;2019:9423907. doi: 10.1155/2019/9423907.

Gong C, Sun K, Xiong HH, Sneh T, Zhang J, Zhou X, Yan P, Wang JH. Expression of CXCR4 and MMP-2 is associated with poor prognosis in patients with osteosarcoma. Histol Histopathol 2020;35(8):863-870. doi: 10.14670/HH-18-219.

Yamahana H, Komiya Y, Takino T, Endo Y, Yamada H, Asada C, Uto Y. Structure-activity relationships of UTX-121 derivatives for the development of novel matrix meta-lloproteinase-2/9 inhibitors. Chem Pharm Bull (Tokyo) 2021;69(10):1017-1028. doi: 10.1248/cpb.c21-00549.

Gieger TL, Nettifee-Osborne J, Hallman B, Johannes C, Clarke D, Nolan MW, Williams LE. The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma. Can J Vet Res 2017;81(3):199-205. PMID: 28725110.

Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol 2006;28(1):33-42. PMID: 16327977.

Kunz P, Sähr H, Lehner B, Fischer C, Seebach E, Fellenberg J. Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma. BMC Cancer 2016;16:223. doi: 10.1186/s12885-016-2266-5.

Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The New- castle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/ programs/clinical_epidemiology/oxford. htm

Benjamin RS, Patel SR. Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy. Cancer Treat Res 2009;152:355-363. doi: 10.1007/978- 1-4419-0284-9_19.

Simpson E, Brown HL. Understanding osteosarcomas. JAAPA 2018;31(8):15-19. doi: 10.1097/01.JAA.0000541477.24116.8d

Kager L, Tamamyan G, Bielack S. Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol 2017;13(4):357-368. doi: 10.2217/fon-2016-0261.

Henriet P, Emonard H. Matrix metallo- proteinase-2: Not (just) a “hero” of the past. Biochimie 2019;166:223-232. doi: 10.1016/j.biochi.2019.07.019.

Fu Z, Xu S, Xu Y, Ma J, Li J, Xu P. The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer. Int J Gynecol Cancer 2015;25(3):356-362. doi: 10.1097/ IGC.0000000000000386.

Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, Song Y. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest 2010;28(6):661-669. doi: 10.3109/07357901003735634.

Shen W, Xi H, Wei B, Chen L. The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis. J Cancer Res Clin Oncol 2014;140(6):1003-1009. doi: 10.1007/ s00432-014-1630-6.